Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Mar;71(3):587–591. doi: 10.1038/bjc.1995.114

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

S Pyrhönen 1, T Kuitunen 1, P Nyandoto 1, M Kouri 1
PMCID: PMC2033628  PMID: 7533517

Abstract

A phase III randomised study, comparing treatment with fluorouracil, epidoxorubicin and methotrexate (FEMTX) with the best supportive care, was conducted in patients with unresectable or metastatic gastric cancer. During the period from July 1986 to June 1992, 41 patients were randomised to receive FEMTX or best supportive care. MTX was given in a dose of 1500 mg m-2 intravenously (i.v.) followed after 1 h by 5-FU 1500 mg m-2 i.v. on day 1; leucovorin rescue was started after 24 h (30 mg orally every 6 h for 48 h) and epidoxorubicin 60 mg m-2 i.v. was administered on day 15. In addition both groups received tablets containing vitamins A and E. Response rates for FEMTX were as follows: complete response (CR), 19% (4/21); partial response (PR), 10% (2/21); no change (NC), 33% (7/21); and progressive disease (PD), 24% (5/21). Response rates in the control group were: NC, 20% (4/20); and PD, 80% (16/20). Increased pain was observed in one patient in the treated group and in 11 patients in the control group within the first 2 months. WHO grade III/IV toxicity in the chemotherapy group was as follows: nausea/vomiting 40%, diarrhoea 10%, stomatitis 15%, leucopenia 50% and thrombocytopenia 10%. One possible treatment-related death was due to sepsis. The median time to progression in the FEMTX group was 5.4 months [95% confidence interval (CI) 3.1-11.7 months], but only 1.7 months in the control group (95% CI 1.2-2.7 months) (P = 0.0013). Similarly, the FEMTX group displayed significantly (P = 0.0006) prolonged survival compared with the control group, i.e. median survival 12.3 months (95% CI 7.1-15.6 months) vs 3.1 months (95% CI 1.6-4.6 months). In conclusion, FEMTX combined with vitamin A and E is a fairly well-tolerated treatment, giving a response rate of 29% in patients with advanced gastric cancer, and also prolonging patients' survival. It can be used as a reference treatment in testing new investigational combinations.

Full text

PDF
587

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cocconi G. Chemotherapy of advanced gastric carcinoma: to be completely rewritten? Ann Oncol. 1994 Jan;5(1):8–11. doi: 10.1093/oxfordjournals.annonc.a058701. [DOI] [PubMed] [Google Scholar]
  2. Cullinan S. A., Moertel C. G., Fleming T. R., Rubin J. R., Krook J. E., Everson L. K., Windschitl H. E., Twito D. I., Marschke R. F., Foley J. F. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061–2067. [PubMed] [Google Scholar]
  3. Dupont J. B., Jr, Lee J. R., Burton G. R., Cohn I., Jr Adenocarcinoma of the stomach: review of 1,497 cases. Cancer. 1978 Mar;41(3):941–947. doi: 10.1002/1097-0142(197803)41:3<941::aid-cncr2820410323>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  4. Ellis P., Cunningham D. Management of carcinomas of the upper gastrointestinal tract. BMJ. 1994 Mar 26;308(6932):834–838. doi: 10.1136/bmj.308.6932.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Findlay M., Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev. 1993 Jan;19(1):29–44. doi: 10.1016/0305-7372(93)90025-m. [DOI] [PubMed] [Google Scholar]
  6. Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kelsen D., Atiq O. T., Saltz L., Niedzwiecki D., Ginn D., Chapman D., Heelan R., Lightdale C., Vinciguerra V., Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541–548. doi: 10.1200/JCO.1992.10.4.541. [DOI] [PubMed] [Google Scholar]
  8. Klein H. O., Wickramanayake P. D., Dieterle F., Mohr R., Oerkermann H., Gross R. High-dose MTX/5-FU and adriamycin for gastric cancer. Semin Oncol. 1983 Jun;10(2 Suppl 2):29–31. [PubMed] [Google Scholar]
  9. Kohnoe S., Yoshida M., Takahashi I., Emi Y., Maehara Y., Sugimachi K. Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells. Anticancer Res. 1992 Mar-Apr;12(2):389–392. [PubMed] [Google Scholar]
  10. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  11. Moertel C. G. The natural history of advanced gastric cancer. Surg Gynecol Obstet. 1968 May;126(5):1071–1074. [PubMed] [Google Scholar]
  12. Murad A. M., Santiago F. F., Petroianu A., Rocha P. R., Rodrigues M. A., Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993 Jul 1;72(1):37–41. doi: 10.1002/1097-0142(19930701)72:1<37::aid-cncr2820720109>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  13. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pyrhönen S. O., Kouri M. O. Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer. Eur J Cancer. 1992;28A(11):1828–1832. doi: 10.1016/0959-8049(92)90014-s. [DOI] [PubMed] [Google Scholar]
  15. Pyrhönen S., Valtonen M. Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract. Lancet. 1990 Jul 14;336(8707):127–127. doi: 10.1016/0140-6736(90)91652-q. [DOI] [PubMed] [Google Scholar]
  16. Wilke H., Preusser P., Fink U., Achterrath W., Meyer H. J., Stahl M., Lenaz L., Meyer J., Siewert J. R., Geerlings H. New developments in the treatment of gastric carcinoma. Semin Oncol. 1990 Feb;17(1 Suppl 2):61–70. [PubMed] [Google Scholar]
  17. Wils J. A. Chemotherapy for gastrointestinal cancer: new hopes or new disappointments? Scand J Gastroenterol Suppl. 1992;194:87–94. doi: 10.3109/00365529209096034. [DOI] [PubMed] [Google Scholar]
  18. Wils J. A., Klein H. O., Wagener D. J., Bleiberg H., Reis H., Korsten F., Conroy T., Fickers M., Leyvraz S., Buyse M. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827–831. doi: 10.1200/JCO.1991.9.5.827. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES